Radequinil
Clinical data
ATC code
  • None
Identifiers
  • 5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H14N4O3
Molar mass334.335 g·mol−1
3D model (JSmol)
  • COc1cccc(c1)c3nccc2NC(=O)\C(=C/c23)c4nc(C)on4
  • InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23)
  • Key:JQOFKKWHXGQABB-UHFFFAOYSA-N

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor.[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.[1][2]

See also

References

  1. ^ a b Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer's Disease" (PDF). The Open Neuropsychopharmacology Journal. 1: 19–23. doi:10.2174/1876523800801010019.
  2. ^ Pogacić V, Herrling P (2007). "List of drugs in development for neurodegenerative diseases. Update June 2007". Neuro-Degenerative Diseases. 4 (6): 443–86. doi:10.1159/000107705. PMID 17934328.


Categories